System operational · UK tenders
Awarded
ocds-h6vhtk-051c3a · award

NHS National Generic Pharmaceuticals - Wave 16a

NHS England

Estimated Value

£15,529,352 – £393,331,872

Deadline

8 June 2026

Published

9 October 2026

Type

Not specified

LondonGBopen

Overview

NHS National Framework for Generics Pharmaceuticals Wave 16a Offer reference number: CM/PHG/24/5714 Period of framework agreement: Dates detailed below, with an option or options to extend (at the authority’s discretion) for a period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: CM/PHG/24/5714/01 Oral (plus non-parenteral) products: CESW/LSNE/NWLN: 01/02/2027 to 31/05/2030 (40 months) CM/PHG/24/5714/02 Hospital only products: DLN: 01/02/2027 to 31/01/2029 (24 months) DNW: 01/02/2027 to 31/01/2029 (24 months) CM/PHG/24/5714/03 Hospital only (housekeeping) products: DCE/DSW: 01/02/2027 to 30/09/2027 (8 months) DLS/DNE: 01/02/2027 to 31/05/2028 (16 months)

AI AnalysisMembers

Requirements, key tasks and tips for reading this tender — included with Tendarix membership.

Create free account

£4.99/month after a 7-day free trial. Cancel anytime before it ends and you pay nothing.

Award Details

ASPIRE PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

BROWN & BURK UK LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

CRESCENT PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

DRUGSRUS LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

ENNOGEN HEALTHCARE INTERNATIONAL LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

FARMAK PHARMACEUTICALS UK LTD

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

FLYNN PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

KENT PHARMA UK LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

Medreich PLC

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

MERCURY PHARMACEUTICALS LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

MILPHARM LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

NECESSITY SUPPLIES LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

NOVUMGEN LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

RPH PHARMA LTD

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

SANDOZ LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

STRIDES PHARMA UK LTD

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

SUN PHARMA UK LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

TEVA UK LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

TORRENT PHARMA (UK) LTD

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

ZENTIVA PHARMA UK LIMITED

27 Aug 20261 Feb 2027 – 31 May 2030

£15,529,352

DR REDDY'S LABORATORIES (UK) LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Accord UK Ltd

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

AFT Pharma UK Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

AGB Pharma (UK) Ltd

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Aguettant Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Amarox Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

FONTUS HEALTH LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

AOP Orphan Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Arcadia Pharma Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ASCEND LABORATORIES (UK) LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ASCOT LABORATORIES LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ASPEN PHARMACARE UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

B. BRAUN MEDICAL LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

BAXTER HEALTHCARE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Biocon Pharma UK Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

BOWMED IBISQUS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

BRANCASTER PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

CELIX PHARMA LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

CHIESI LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

CIPLA (EU) LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

CLINIGEN HEALTHCARE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

COLONIS PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

CONSILIENT HEALTH (UK) LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

C. S. T. PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

DAY LEWIS MEDICAL LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

DESITIN PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ERAMOL (UK) Limited

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ESTEVE PHARMACEUTICALS LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

FERRING PHARMACEUTICALS LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

FLEXIPHARM AUSTRADING LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

FRESENIUS KABI LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

GALVANY PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

GENNISIUM PHARMA

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

GILEAD SCIENCES LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

GLAXOSMITHKLINE UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

HAMELN PHARMA LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

GLENMARK PHARMACEUTICALS EUROPE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

GRINDEKS KALCEKS UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

HIKMA PHARMACEUTICALS INTERNATIONAL LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Lipomed GmbH

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

LUNDBECK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

MACLEODS PHARMA UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

MACURE PHARMA UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

MACARTHYS LABORATORIES LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

MEDAC PHARMA LLP

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

MORNINGSIDE PHARMACEUTICALS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

MSN LABORATORIES EUROPE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

NEON HEALTHCARE LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

NEURAXPHARM UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

NORTHUMBRIA PHARMA THROMBOSIS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

NOVARTIS PHARMACEUTICALS UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Orifarm UK Ltd

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

OTSUKA PHARMACEUTICALS (U.K.) LTD.

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PANPHARMA UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PARI MEDICAL LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PERENNIAL PHARMA LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PFIZER LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Phoenix labs U.C.

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PIERRE FABRE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PIRAMAL CRITICAL CARE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

PROVEPHARM UK LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

REIG JOFRE UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

RIDGE PHARMA LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ROCHE PRODUCTS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ROVI BIOTECH LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

SEACROSS PHARMACEUTICALS LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

SELECTIVE SUPPLIES LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

SERB LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

SVP PHARMA LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

SYNCHRONY PHARMA

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

TAKEDA UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

THEA PHARMACEUTICALS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

THORNTON & ROSS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Tillomed Laboratories Ltd

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

TORBAY PHARMACEUTICALS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

UNICORN PHARMACEUTICALS LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

USV UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

VANTAGE PHARMACEUTICALS LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

WAYMADE PLC

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

VIATRIS UK HEALTHCARE LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

WOCKHARDT UK LIMITED

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

ZYDUS PHARMACEUTICALS UK LTD

27 Aug 20261 Feb 2027 – 31 Jan 2029

£393,331,872

Likely incumbents

Suppliers who won similar work from this buyer in the last 5 years.

5 found
  1. 1

    Sheffield Teaching Hospitals NHS Foundation Trust

    7 contracts wonlatest 22 Sept 2026

    £780m

    total awarded

  2. 2

    The Newcastle upon Tyne Hospitals NHS Foundation Trust

    7 contracts wonlatest 22 Sept 2026

    £794m

    total awarded

  3. 3

    ACCORD-UK LTD

    7 contracts wonlatest 15 Jun 2026ends 31 Aug 2028

    £2bn

    total awarded

  4. 4

    NHS Business Services Authority

    6 contracts wonlatest 29 Sept 2026ends 31 Mar 2027

    £55m

    total awarded

  5. 5

    NHS BSA

    6 contracts wonlatest 13 Aug 2026ends 31 Mar 2027

    £66m

    total awarded

Sheffield Teaching Hospitals NHS Foundation Trust is the most likely incumbent based on recency and category match. To win, bidders typically need a clearly differentiated proposition or a price advantage.

Search for tenders
SponsoredEst. 2010
Gladstone & Co AccountantsTax advisers · East Ham, London

Before you bid, buyers check

two years of filed accountsyour financial standingturnover vs contract valueyour Companies House recordcash flow for 30-day termscredit scores and ratios

Annual accountsCash-flow forecastsManagement accountsCorporation taxVAT & MTDPayroll & RTIBookkeepingCompany formationSelf-assessmentVirtual FDHMRC enquiriesAuto-enrolmentProperty & landlord taxCharity SORP accounts
Get bid-ready — free 30-min call

Actions

Start free trialto open noticeStart free trial to download

Create an account and start a 7-day free trial to open the buyer’s own notice and tender documents, plus fit scoring and the Bid Writer. Then £4.99/month — cancel anytime.

Open Bid Writer
Built by · Digital studioEst. 2022
Unique
Evolution®

Independent software, web & cloud studio. We design, build and grow digital products that quietly outlast their category.

Web DesignSoftware DevelopmentSEO ServicesPromotion
Visit Unique Evolution

How to Apply

Step-by-step submission guide

Closed

Submission Portal

Find a Tender

Visit
1

Open the original notice

Click the button below to view the full notice on Find a Tender Service (FTS)

2

Check the procedure type

The "Procedure" section tells you if it's Open (one stage) or Restricted (SQ then ITT). This changes how you apply

3

Access the eSourcing portal

FTS notices link to the buyer's eSourcing platform — register there to access documents

4

Complete the Selection Questionnaire

Higher-value contracts often require an SQ first — this pre-qualifies you before the full bid stage

5

Submit electronically

Upload your completed response through the eSourcing platform before the closing date and time

FTS contracts are above UK procurement thresholds. Late submissions are strictly rejected — submit at least 24 hours before the deadline to avoid portal issues.

Buyer Profile

NHS England
Typepublic body
RegionNorth East,North West,Yorkshire and The Humber,East Midlands,West Midlands,East of England,London,South East,South West,Scotland,Wales,Northern Ireland
Total tenders1,496
Total spend£160,377,968,665
View buyer profile

Key Dates

Published

9 October 2026

Submission deadline

8 June 2026

Notice type

award

Source

find a tender